ArticleInfection and drug resistance2026
Clinical Value of Contrast-Enhanced Ultrasound and Ultrasound Elastography in the Pathological Classification and Treatment Response Prediction of Cervical Tuberculous Lymphadenitis.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Limited evidence exists on imaging-based classification and treatment response prediction in cervical tuberculous lymphadenitis (CTL). This study aimed to investigate the clinical value of contrast-enhanced ultrasound (CEUS) and ultrasound elastography (UE) in differentiating pathological subtypes of CTL and predicting response to anti-tuberculosis therapy. Methods: This retrospective cohort study included 120 patients with CTL confirmed by pathological examination between January 2021 and October 2025. All patients underwent CEUS and UE prior to treatment. Parameters including the non-perfusion area ratio, enhancement pattern, strain ratio, and elasticity score were recorded. Using pathological diagnosis as the reference standard, the diagnostic performance of CEUS and UE for different pathological subtypes was evaluated. Based on the lymph node volume reduction rate (VRR) at 6 months after treatment, patients were classified into a treatment-sensitive group (VRR ≥ 50%) and a treatment-insensitive group (VRR < 50%). The associations between imaging parameters and treatment response were analyzed. Results: The proportion of annular enhancement on CEUS, non-perfusion area ratio, proportion of high elasticity scores on UE, and strain ratio were significantly higher in Type II patients than in Type I and Type III patients (all P < 0.05). CEUS and UE yielded sensitivities of 87.5% and 85.0% and specificities of 87.5% and 76.3%, respectively. Strain ratio, non-perfusion area ratio, and disease duration were independent risk factors for treatment insensitivity. The predictive model combining CEUS and UE parameters showed superior performance compared with either modality alone. Conclusion: CEUS and UE can noninvasively and effectively differentiate pathological subtypes of CTL, with particularly high diagnostic accuracy for Type II (caseous necrosis). We recommend incorporating CEUS and UE into the pre-treatment evaluation of CTL to guide subtype identification and risk stratification for anti-tuberculosis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.